# Mechanism of Ocrelizumab in B-Cell Depletion ## How does ocrelizumab target CD20-positive B cells to drive B-cell depletion? Ocrelizumab binds to CD20 on B cells and drives their depletion primarily through antibody-dependent cellular cytotoxicity mediated by monocytes via Fcγ receptor pathways, achieving rapid and sustained reduction of circulating B cells while also depleting CD20-positive T-cell subsets. # Abstract Ocrelizumab is a humanized anti-CD20 monoclonal antibody that targets the same CD20 epitope as rituximab but achieves B-cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) rather than complement-dependent cytotoxicity (CDC). The antibody was engineered with amino acid modifications to enhance binding to Fcγ receptor IIIa, resulting in two- to five-fold greater ADCC activity compared to rituximab. Monocytes serve as the dominant effector cells mediating B-cell depletion through FcγRI and FcγRIII-dependent pathways, achieving rapid onset within hours and near-complete depletion (>95%) of circulating B cells by week 2. However, depletion efficiency varies across anatomical compartments, with secondary lymphoid organs retaining resistant B-cell subpopulations and bone marrow showing the weakest reduction. Ocrelizumab also co-depletes CD20-positive T-cell subsets and novel dual-expressor lymphocytes expressing both T-cell and B-cell receptors. B-cell recovery begins in bone marrow and spleen before appearing in blood, with median time to repletion of 72 weeks. The phenotype of reconstituting B cells varies by immunological context: in settings with ongoing antigen stimulation, recovery is characterized by expansion of differentiated, myelin-reactive B cells, whereas absence of stimulation favors naive B-cell reconstitution. Treatment induces secondary immunological changes including increased BAFF levels and decreased sTACI, which may enhance regulatory plasma cell development and contribute to therapeutic efficacy. The ADCC-predominant mechanism provides more sustained depletion than CDC-predominant antibodies while potentially offering better tolerability. # Methods We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. More on methods Records from Elicit search - n = 200 ## Papers screened using: - Mechanistic Focus on CD20/B-cells - Specific Depletion Mechanisms - Study Type and Mechanistic Data - Mechanistic Content Present - CD20/B-cell Relevance - Study Rigor and Detail - n = 200 Papers screened out - n = 190 Papers included for extraction - n = 10 ## Results ### Characteristics of Included Studies | Study | Full text retrieved? | Study focus | Key features | |---|---|---|---| | J. Uchida et al., 2004 | Yes | Mouse model of anti-CD20 therapy | Developed mouse anti-mouse CD20 antibody panel to study B-cell depletion mechanisms | | B. Cree et al., 2025 | Yes | Review of anti-CD20 antibody evolution | Comprehensive comparison of ocrelizumab, ofatumumab, ublituximab, and rituximab | | Pacheco-Fernández et al., 2018 | No | In vitro CDC comparison | Compared ofatumumab and ocrelizumab CDC activity using B-cell lines | | Samantha Ho et al., 2023 | Yes | B-cell regulating factors | Examined effects on BAFF-APRIL system over 2.5 years | | Schneider-Hohendorf et al., 2025 | No | B- and T-cell receptor repertoires | Analyzed adaptive immune changes in 35 MS patients on ocrelizumab | | Alice Willison et al., 2025 | Yes | Immune cell dynamics comparison | Compared ocrelizumab (n=34) and ofatumumab (n=25) with flow cytometry | | A. Bar-Or et al., 2021 | Yes | Clinical perspectives review | Detailed molecular and pharmacological attributes of four anti-CD20 antibodies | | Darius Häusler et al., 2018 | Yes | EAE model of B-cell recovery | Characterized B-cell depletion and reconstitution in murine MS model | | S. A. Kornilov et al., 2024 | No | Multi-omic characterization | Analyzed plasma proteome, metabolome, and lipidome changes in 14 RRMS patients | | Prajita Paul et al., 2025 | No | Dual-expressor lymphocytes | Identified novel TCR/IgM dual-expressor cells susceptible to anti-CD20 therapy | ## Mechanisms of CD20 Targeting and B-cell Depletion ### CD20 Binding Characteristics Ocrelizumab is a humanized anti-CD20 monoclonal antibody that binds to the same epitope on the large extracellular loop of CD20 as rituximab. The antibody is classified as a type I anti-CD20 agent capable of crosslinking CD20 tetramers. Enhanced binding to low-affinity variants of Fcγ receptor IIIa distinguishes ocrelizumab from rituximab, contributing to its enhanced effector function. The antibody was specifically engineered through amino acid modifications in its Fc region to increase antibody-dependent cellular cytotoxicity (ADCC) activity. ### Cytotoxic Mechanisms Ocrelizumab depletes B cells through multiple cytotoxic pathways, with ADCC as the primary mechanism. The antibody exhibits two- to five-fold greater ADCC activity compared to rituximab, while demonstrating three- to five-fold lower complement-dependent cytotoxicity (CDC) activity. Both ocrelizumab and ofatumumab can induce ADCC and CDC, though ofatumumab demonstrates stronger CDC effects, particularly at low CD20 expression levels. The dominance of ADCC over CDC in ocrelizumab’s mechanism of action has important implications. Studies in mouse models demonstrated that B-cell depletion is completely dependent on effector cell Fc receptor expression, with monocytes serving as the dominant effector cells. ## Patterns of B-cell Depletion Ocrelizumab targets CD20-positive B cells, resulting in significant reductions across multiple B-cell subsets including naive B cells, memory B cells, transitional B cells, and plasmablasts. Plasma cells, which lack CD20 expression, remain resistant to depletion, as do CD20-negative B-cell precursors and hematopoietic stem cells. Broadly, ocrelizumab co-depletes CD20-positive T-cell subsets, with significant reductions in double-negative (CD3+CD4−CD8−) T cells. ## Kinetics of Depletion and Recovery The onset of B-cell depletion is rapid, with near-complete depletion observed by week 2 following the first dose. Recovery patterns can vary by anatomical compartment and B-cell phenotype. ### Recovery Patterns B-cell recovery follows a complex timeline across different compartments, with a median time to repletion of 72 weeks and variations in phenotype seen based on prior immunological context during recovery. This recovery process is significantly tied to disease activity, where early reconstitution of B-cell populations correlates to potential clinical outcomes. ## Comparative Analysis with Other Anti-CD20 Antibodies Ocrelizumab exhibits mechanistic distinctions when compared to other anti-CD20 antibodies, particularly in its reliance on ADCC over CDC. The comparative analysis suggests that while different antibodies achieve effective B-cell depletion, the mechanisms and dosing implications differ, emphasizing the need for tailored therapeutic approaches. ## Secondary Effects on Immune Regulation Treatment with ocrelizumab results in notable changes within the BAFF-APRIL system and associated immune regulatory networks, reinforcing the therapeutic implications of B-cell modulation and adaptive immunity. ## Synthesis In conclusion, the mechanism by which ocrelizumab drives B-cell depletion is multifaceted, with implications spanning anatomical, immunological, and therapeutic domains. Understanding these intricacies may aid in optimizing treatment strategies in patients receiving anti-CD20 therapies.